


# The Claim Amendments

Please amend the claims as follows:

- (Currently amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof; wherein

Y is selected from  $-(CH_2)-Q_1$ ;  $-(CO)-Q_1$ ;  $-(CO)NH-Q_1$ ;  $-(CO)-O-Q_1$ ;  $-(SO_2)-Q_1$  or  $-(SO_2)NH-Q_1$ ;

$Q_1$  is a  $C_1-C_6$  straight chain or branched alkyl or alkenyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system, wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected from  $NH_2$ ,  $NH-R$ ,  $N(R)_2$ ,  $NO_2$ ,  $OH$ ,  $OR$ ,  $CF_3$ , halo,  $CN$ ,  $CO_2H$ ,  $C(O)-NH_2$ ,  $C(O)-NH-R$ ,  $C(O)-N(R)_2$ ,  $C(O)-R$ ,  $SR$ ,  $S(O)-R$ ,  $S(O)_2-R$ ,  $S(O)_2-NH-R$  or  $-R$ ;

$R^1$  is  $-NHR^5$ ,  $-OR^5$ ,  $-SR^5$ , or  $-R^5$ ;

$R^2$ ,  $R^3$ , and  $R^4$  are independently selected from  $-(CO)NH_2$ ,  $-(CO)NHR$ ,  $-(CO)N(R)_2$ ,  $-NHR^5$ ,  $-NHCH_2R^5$ ,  $-OR^5$ ,  $-SR^5$ ,  $-R^5$ ,  $-NH(CO)-R^6$ ,  $-NH(CO)-NHR^6$ ,  $-NH(CO)-NH(CO)R^6$ ,  $-NH(CO)-OR^6$ ,  $-NH(SO_2)-R^6$ ,  $-NH(SO_2)-NHR^6$ ,  $-C(O)OH$ ,  $-C(O)OR$ ,  $-(CO)-Q_1$ ,  $-(CO)NH-Q_1$ ,  $-(CO)NR-Q_1$ ,  $-(CO)-O-Q_1$ ,  $-(SO_2)-Q_1$  or  $-(SO_2)NH-Q_1$ ;

$R^5$  and  $R^6$  are each independently selected from  $H$ ;  $N(R)_2$ ,  $NHOH$ ,  $NO_2$ ,  $C(O)OR$  or halo; a  $C_1-C_6$  straight chain or branched alkyl, alkenyl or alkynyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14

membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring; wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected from  $\text{NH}_2$ ,  $\text{NHR}$ ,  $\text{NHC(O)OR}$ ,  $\text{N(R)}_2$ ,  $\text{NO}_2$ ,  $\text{OH}$ ,  $\text{OR}$ ,  $\text{CF}_3$ , halo,  $\text{CN}$ ,  $\text{Si(R)}_3$ ,  $\text{CO}_2\text{H}$ ,  $\text{COOR}$ ,  $\text{CONH}_2$ ,  $\text{CONHR}$ ,  $\text{CON(R)}_2$ ,  $\text{COR}$ ,  $\text{SR}$ ,  $\text{S(O)R}$ ,  $\text{S(O)}_2\text{R}$ ,  $\text{S(O)}_2\text{NHR}$  or  $\text{R}$ ;

$\text{R}$  is a  $\text{C}_1\text{-C}_6$  straight chain or branched alkyl or alkenyl group, a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring, or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system.

~~provided that:~~

~~when  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ , and  $\text{R}_4$  are  $\text{H}$ , then  $\text{Y}$  is not 2,2-diethoxyethyl, 2-chloro-ethyl, 4-chloro-butyl, ethyl, 2-hydroxyethyl, methyl, isopropyl, or unsubstituted benzyl; when  $\text{R}_1$ ,  $\text{R}_3$ , and  $\text{R}_4$  are  $\text{H}$ , and  $\text{R}_2$  is  $\text{Br}$ , then  $\text{Y}$  is not unsubstituted benzyl, ethyl, or methyl; when  $\text{R}_1$  and  $\text{R}_3$  are  $\text{CH}_3$ , and  $\text{R}_2$  and  $\text{R}_4$  are  $\text{H}$ , then  $\text{Y}$  is not ethyl; when  $\text{R}_1$  and  $\text{R}_3$  are  $\text{H}$ , and  $\text{R}_2$  and  $\text{R}_4$  are  $\text{Cl}$ , then  $\text{Y}$  is not ethyl; and when  $\text{R}_1$ ,  $\text{R}_2$  and  $\text{R}_4$  are  $\text{H}$ , and  $\text{R}_3$  is  $\text{CH}_3$ , then  $\text{Y}$  is not ethyl.~~

2-15. Canceled.

16. (Previously presented) The compound of claim 1, wherein  $\text{Y}$  is  $-(\text{CH}_2)\text{-Q}_1$  and  $\text{Q}_1$  is optionally substituted benzodioxanyl.

17. (Previously presented) The compound of claim 1, wherein  $\text{R}^1$  is  $\text{R}^5$ .

18. (Previously presented) The compound of claim 1, wherein  $\text{R}^1$  is  $\text{H}$ , methyl, halo, optionally substituted phenyl, a monocyclic or bicyclic heterocycle, optionally substituted alkyl, alkenyl or alkynyl, or  $\text{COOR}$ .

19. (Previously presented) The compound of claim 1, wherein  $R^2$  is  $R^5$ ,  $NH(CO)-R^6$ ,  $NH(SO_2)-R^6$ ,  $-NHCH_2R^5$ ,  $CO-Q_1$  or  $CONH-Q_1$ .

20. (Previously presented) The compound of claim 1, wherein  $R^2$  is H, halo,  $NO_2$ ,  $NH_2$ , methyl,  $OCF_3$ ,  $-N(R)_2$ , or substituted phenyl.

21. (Previously presented) The compound of claim 1, wherein  $R^3$  is  $R^5$ ,  $NH(CO)-R^6$ ,  $NH(SO_2)-R^6$ , or  $CONH-Q_1$ .


22. (Previously presented) The compound of claim 1, wherein  $R^3$  is H, halo, methyl,  $CF_3$ , optionally substituted phenyl, a heterocyclic ring, a bicyclic ring,  $NO_2$  or  $NH_2$ .

23. (Previously presented) The compound of claim 1, wherein  $R^4$  is  $R^5$ .


24. (Previously presented) The compound of claim 1, wherein  $R^4$  is H or methyl.

25-27. Canceled.


28. (New) The compound according to claim 1, wherein said compound is selected from the group depicted below:




64




65




69




70




71




75




76




77




81




85




86




90




91




95




96




103




104




108




109




110




111




112




113




118




122




124



127




129




132

11884-1


Page 7 of 52




135




138




141




148




149




152



153




154




156

11884-1


Page 8 of 52




159




160




161




163




165



167




168




169







170




172




173




174




175




177




178




179




181




182




183




184




186




187



188




190



191


192

193




195

196




201


202




203




204




205




206




207




208




209




210




211




212




213




214




215




216




217




218




219




220




221




222




223




224




225




226




227




228




229




230




231




232




233




234




235




236




237




238




239




240




241




242



243




244




246







247




248




249




250




251




252




253




254




255




256




257




258




259




260




261




262




263




264




265




266




268




269




270




271




272




273




274




275




276




277




278




280




281





282




283




284




285




286




287




288



289




290




291


292




293




294




295




296




297




298




299




300




301




302




303



304




305




306







307




308




309




310




311




312




313




314




315




316




318




319




320




321




322




323




324




325




326




327




328




329




330




331




332




333




334




335




336




337




338




339




340




341




342




343




344




345




346




348




349




350




351




352



353



355




356

29. (New) A pharmaceutical composition comprising a compound according to either of claims 1 or 28 and a pharmaceutically acceptable carrier.

30. (New) A method for treating Parkinson's disease in a patient in need thereof, comprising administering the pharmaceutical composition of claim 29 to the patient.

31. (New) A compound of the formula:



or a pharmaceutically acceptable salt thereof; wherein

Y is  $-(CH_2)-Q_1$ ;

$Q_1$  is benzodioxanyl, a substituted phenyl group, a substituted 5-7 membered aromatic heterocyclic ring, a 10-membered heterocyclic bicyclic ring, or a straight chain alkyl group substituted with phenyl or a heterocyclic monocyclic or bicyclic ring, wherein said phenyl or heterocyclic ring is substituted with one to four substituents, each of which is independently selected from  $NH_2$ ,  $NH-R$ ,  $N(R)_2$ ,  $NO_2$ ,  $OH$ ,  $OR$ ,  $CF_3$ , halo,  $CN$ ,  $CO_2H$ ,  $C(O)-NH_2$ ,  $C(O)-NH-R$ ,  $C(O)-N(R)_2$ ,  $C(O)-R$ ,  $SR$ ,  $S(O)-R$ ,  $S(O)_2-R$ ,  $S(O)_2-NH-R$  or  $-R$ ;

$R^1$  is  $R^5$ ;

$R^2$  is  $OCF_3$ ,  $NH_2$ ,  $R^5$ ,  $NH(CO)-R^6$ ,  $NH(SO_2)-R^6$ ,  $-NHCH_2R^5$ ,  $CO-Q_1$  or  $CONH-Q_1$ ;

$R^3$  is  $NH(CO)-R^6$ ,  $NH(SO_2)-R^6$ ,  $CONH-Q_1$ ,  $H$ , halo, methyl,  $CF_3$ , substituted or unsubstituted phenyl, a substituted or unsubstituted aromatic heterocyclic ring, an aromatic bicyclic ring,  $NO_2$  or  $NH_2$ ;

$R^4$  is  $R^5$ ;

$R^5$  and  $R^6$  are each independently selected from  $H$ ;  $N(R)_2$ ,  $NHOH$ ,  $NO_2$ ,  $C(O)OR$  or halo; a  $C_1-C_6$  straight chain or branched



alkyl, alkenyl or alkynyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring; wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected from  $\text{NH}_2$ ,  $\text{NHR}$ ,  $\text{NHC(O)OR}$ ,  $\text{N(R)}_2$ ,  $\text{NO}_2$ ,  $\text{OH}$ ,  $\text{OR}$ ,  $\text{CF}_3$ , halo,  $\text{CN}$ ,  $\text{Si(R)}_3$ ,  $\text{CO}_2\text{H}$ ,  $\text{COOR}$ ,  $\text{CONH}_2$ ,  $\text{CONHR}$ ,  $\text{CON(R)}_2$ ,  $\text{COR}$ ,  $\text{SR}$ ,  $\text{S(O)R}$ ,  $\text{S(O)}_2\text{R}$ ,  $\text{S(O)}_2\text{NHR}$  or  $\text{R}$ ; and

$\text{R}$  is a  $\text{C}_1\text{-C}_6$  straight chain or branched alkyl or alkenyl group, a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring, or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system.

32. (New) The compound according to claim 31, wherein  $\text{R}^1$  is  $\text{H}$ , methyl, halo, an optionally substituted phenyl, a monocyclic or bicyclic heterocycle, a substituted or unsubstituted alkyl, alkenyl or alkynyl, or  $\text{COOR}$ .


33. (New) The compound according to claim 31, wherein  $\text{R}^2$  is  $\text{H}$ , halo,  $\text{NO}_2$ ,  $\text{NH}_2$ , methyl,  $\text{OCF}_3$ ,  $\text{-N(R)}_2$ , or substituted phenyl.

34. (New) The compound according to claim 31, wherein  $\text{R}^3$  is  $\text{H}$ , halo, methyl,  $\text{CF}_3$ , substituted or unsubstituted phenyl, an aromatic heterocyclic ring, a bicyclic ring,  $\text{NO}_2$  or  $\text{NH}_2$ .


35. (New) The compound according to claim 31, wherein  $\text{R}^4$  is  $\text{H}$  or methyl.

36. (New) The compound according to claim 31, wherein  $\text{Q}_1$  is a substituted phenyl group.


37. (New) The compound according to claim 36, wherein said compound is selected from the group depicted below:




1




2




3




4




5




6




7




8




9













10















11




12









38




39




40




41




42




43




44




46




47




48




49




50




51




52




54




55




56




57




58




59




60




61




62




63




66




67




68




72




73




74




78




79




80




82




83




84




87




88




89



92




93




94







97




98




99




100




101




102




105




106




107




121




131




134




137




140




143




145




147




150




151




162




164




166




171




176




180




185




198



199



200



354

38. (New) A pharmaceutical composition comprising a compound according to either of claims 31 or 37 and a pharmaceutically acceptable carrier.

39. (New) A method for treating Parkinson's disease in a patient in need thereof, comprising administering the pharmaceutical composition of claim 38 to the patient.